title: Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.
abstract: The aim of this study was to determine the maximum-tolerated dose (MTD) of weekly oxaliplatin combined with 5-fluorouracil (5FU) continuous infusion administered concomitantly with fractionated radiotherapy in patients presenting advanced rectal cancer. Forty-three patients with rectal cancer (stage T3/T4 (n = 24), metastatic (n = 17) and 2 with local recurrence), were included. The radiotherapy dose delivered was 45 Gy over 5 weeks (1.8 Gy/fraction/day, 5 days per week). The initial weekly oxaliplatin dosage was 30 mg/m2 and the 5FU dosage 150 mg/m2/d. The oxaliplatin and 5FU doses were escalated. Eight dose levels were tested. At dose level 8 (oxaliplatin 80 mg/m2, 5FU 225 mg/m2/d), 2 patients out of 4 presented dose-limiting toxicity (severe diarrhoea with dehydration and fatal shock, rectovesical fistula). At dose level 7, 2 further patients presented with grade 3 diarrhoea. The main toxicity of the combination was diarrhoea. The hematological and neurological toxicities were not severe and were not dose-limiting. Out of the 30 patients undergoing surgery, 4 (13.3%) presented with pathological complete response and 4 (13.3%) only presented with microscopic residual disease. The results from this study enabled determination of the recommended weekly oxaliplatin dose (60 mg/m2) combined with 5FU continuous infusion (225 mg/m2) and fractionated radiotherapy (45 Gy) in the pre-operative treatment of advanced rectal cancer. The good safety profile of the regimen, associated with promising results in terms of histological response, suggest that the regimen could be developed in future phase II/III studies.
authors.affiliation: Department of Medical Oncology, Centre Antoine-Lacassagne, Avenue de Valombrose, 06189 Nice, Cedex 2, France. eric.francois@nice.fnclcc.fr
authors.forename: Eric
authors.initials: E
authors.lastname: François
authors.forename: Marc
authors.initials: M
authors.lastname: Ychou
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
authors.forename: Frédérique
authors.initials: F
authors.lastname: Bertheault-Cvitkovic
authors.forename: Marc
authors.initials: M
authors.lastname: Giovannini
authors.forename: Thierry
authors.initials: T
authors.lastname: Conroy
authors.forename: Claire
authors.initials: C
authors.lastname: Lemanski
authors.forename: Olivier
authors.initials: O
authors.lastname: Thomas
authors.forename: Valérie
authors.initials: V
authors.lastname: Magnin
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D010808:Physical Examination; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil